Psyence Biomedical (PBM) Competitors $3.61 -0.09 (-2.43%) Closing price 04:00 PM EasternExtended Trading$3.64 +0.02 (+0.69%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. TAOX, PMN, SNYR, ALLR, NNVC, LIXT, LPTX, FBLG, GDTC, and LSTAShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Synaptogenix (TAOX), Promis Neurosciences (PMN), Synergy CHC (SNYR), Allarity Therapeutics (ALLR), NanoViricides (NNVC), Lixte Biotechnology (LIXT), Leap Therapeutics (LPTX), FibroBiologics (FBLG), CytoMed Therapeutics (GDTC), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors Synaptogenix Promis Neurosciences Synergy CHC Allarity Therapeutics NanoViricides Lixte Biotechnology Leap Therapeutics FibroBiologics CytoMed Therapeutics Lisata Therapeutics Psyence Biomedical (NASDAQ:PBM) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk. Do institutionals & insiders have more ownership in PBM or TAOX? 77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is PBM or TAOX more profitable? Psyence Biomedical's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Psyence BiomedicalN/A N/A N/A Synaptogenix N/A -277.76%-150.79% Which has preferable earnings & valuation, PBM or TAOX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPsyence BiomedicalN/AN/A$1.01MN/AN/ASynaptogenixN/AN/A-$12.77M-$20.16-0.34 Does the media prefer PBM or TAOX? In the previous week, Psyence Biomedical and Psyence Biomedical both had 3 articles in the media. Psyence Biomedical's average media sentiment score of 0.95 beat Synaptogenix's score of 0.63 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PBM or TAOX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, PBM or TAOX? Psyence Biomedical has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. SummaryPsyence Biomedical beats Synaptogenix on 6 of the 7 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.74M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A22.1185.3526.57Price / SalesN/A416.63582.95179.01Price / Cash2.4847.1938.3262.20Price / Book0.3110.2112.726.53Net Income$1.01M-$52.40M$3.30B$275.87M7 Day Performance12.11%0.90%1.07%-1.40%1 Month Performance13.17%12.36%7.61%5.16%1 Year Performance-93.39%30.17%79.71%31.51% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence Biomedical1.5214 of 5 stars$3.61-2.4%N/A-93.3%$6.74MN/A0.00N/ANews CoverageAnalyst ForecastTAOXSynaptogenix0.1842 of 5 stars$6.77+3.4%N/AN/A$23.63MN/A-0.344News CoverageAnalyst ForecastGap UpPMNPromis Neurosciences3.2332 of 5 stars$0.44+2.4%$4.33+896.2%-50.5%$23.35MN/A-2.075Positive NewsAnalyst ForecastGap UpSNYRSynergy CHC3.8773 of 5 stars$2.47+1.2%$10.00+304.9%N/A$23.32M$33.70M6.5040Analyst ForecastALLRAllarity Therapeutics2.7219 of 5 stars$1.60+1.3%$9.25+478.1%+19.7%$23.23MN/A0.0010Analyst ForecastNNVCNanoViricides0.2536 of 5 stars$1.44+0.3%N/A+3.3%$23.06MN/A-1.9920LIXTLixte Biotechnology0.6457 of 5 stars$4.87-3.2%N/A+169.7%$22.21MN/A-3.784Analyst ForecastLPTXLeap Therapeutics2.5734 of 5 stars$0.54+17.8%$3.38+530.8%-70.9%$22.17MN/A-0.3440News CoverageAnalyst ForecastGap DownHigh Trading VolumeFBLGFibroBiologics2.4022 of 5 stars$0.53-2.8%$12.67+2,285.4%-81.1%$22.16MN/A-1.4710Analyst ForecastGDTCCytoMed Therapeutics0.2686 of 5 stars$2.01+0.8%$5.00+149.3%+10.8%$21.95M$69.50K0.00N/AAnalyst ForecastLSTALisata Therapeutics2.4307 of 5 stars$2.50-4.6%$23.50+840.0%-20.6%$21.90M$1M-1.1230News CoverageAnalyst Forecast Related Companies and Tools Related Companies Synaptogenix Alternatives Promis Neurosciences Alternatives Synergy CHC Alternatives Allarity Therapeutics Alternatives NanoViricides Alternatives Lixte Biotechnology Alternatives Leap Therapeutics Alternatives FibroBiologics Alternatives CytoMed Therapeutics Alternatives Lisata Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
